Resumo

OVILLA-MARTINEZ, Roberto; BAEZ-ISLAS, Pamela E.; COTA-RANGEL, Xóchitl  e  PENA-CELAYA, Antonio de la. New therapeutic options for the COVID-19 patient. The experience from the hematologist. Gac. Méd. Méx [online]. 2021, vol.157, suppl.3, pp.S23-S28.  Epub 25-Abr-2022. ISSN 2696-1288.  https://doi.org/10.24875/gmm.m21000466.

In the current SARS-CoV-2 pandemic, it has been observed that the main complications arise as a result of the release of multiple cytokines such as IL-1, IL-6, TNF-α and type 1 interferons that generate a proinflammatory state characterized by lung tissue injury and subsequently multiple organ failure. In the hematology field, there is experience in the use of various drugs designed to limit these cytokines which have already been used in patients with COVID-19 including IL-6 inhibitors such as tocilizumab, sarilumab, and siltuximab; the IL-1 inhibitor anakinra; and the janus kinase inhibitors ruxolitinib and baricitinib. Knowing the pathophysiological basis of COVID-19, the usefulness of this type of drugs show encouraging results for moderate to severe symptoms of the disease and encourages its use in larger clinical trials.

Palavras-chave : COVID-19; Tocilizumab; Sarilumab; Siltuximab; Baricitinib; Ruxolitinib.